Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Abstracts

Clinical pathology selected abstracts

December 2024—Excitement over the impact of artificial intelligence-based tools in different areas of health care has prompted position papers and research on the application of these new devices. One such tool is ChatGPT, which is publicly available and has demonstrated domain-specific knowledge in numerous areas, including medicine. The vast amount of data generated with current technologies, including digital pathology applications, and in subspecialty areas of pathology may lend itself to interpretation with artificial intelligence-based algorithms. But while AI-based applications can automate routine tasks and enhance diagnostic accuracy, their widespread use has been limited. Further AI research and validation of AI-based applications will increase adoption of such technology and, thereby, the overall efficiency and accuracy of the diagnostic process in pathology.

Anatomic pathology selected abstracts

December 2024—Recurrence of Crohn’s disease within one or two years of resection is common. The authors conducted a study in which they sought to identify histologic features in Crohn’s disease resections that may predict earlier recurrence (18 months or less) to potentially guide postoperative management. They performed a single-institution, retrospective database review of 41 patients who had first-time Crohn’s disease bowel resection specimens collected between October 2002 and December 2007. Patient demographics and Crohn’s disease course were documented. Slides were reviewed for the distribution and composition of inflammation, small bowel pyloric metaplasia, and the presence and characteristics of submucosal fibrosis and granulomas.

Molecular pathology selected abstracts

December 2024—Acute promyelocytic leukemia is generally characterized by presence of the PML::RARA fusion. However, a subset of cases with morphological, cytochemical, and immunophenotypic features of acute promyelocytic leukemia (APL) lack this canonical fusion gene and instead present with alternate fusions. These include RARA fusions with partners other than PML and fusions involving other retinoic acid receptor (RAR) genes, such as RARG. Leukemias with these variant fusions often resist all-trans retinoic acid (ATRA) therapy. Specifically, the ATRA sensitivity of RARA fusion genes varies based on its 5′ fusion partner. Interestingly, in some studies, the artificially induced variant RAR bipartite fusion genes responded well to ATRA.

Clinical pathology selected abstracts

November 2024—Pathology training programs are meant to prepare trainees for the workforce by imparting medical knowledge and developing skills in diagnostic interpretation in anatomic pathology. Yet transitioning to the workforce can be challenging for some new graduates. To address this, many training programs have begun teaching management and leadership skills that are required on the job. In addition, the College of American Pathologists New in Practice Committee developed online educational material to provide practical advice for those starting their pathology careers.

Anatomic pathology selected abstracts

November 2024—Inactivating alterations in switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex subunits have been described in multiple tumor types. Recent studies focused on SMARC subunits of this complex to explain their relationship with tumor characteristics and therapeutic opportunities. Pancreatic cancer with these alterations has not been well studied, although isolated cases of undifferentiated carcinomas have been reported.

Molecular pathology selected abstracts

November 2024—Many people with an intellectual disability do not receive a molecular diagnosis following genetic testing. While 1,427 genes have been confidently identified as etiological for an intellectual disability (ID), all but nine of them are protein coding. To identify noncoding etiologies of ID, the authors conducted a genetic association analysis using whole genome sequencing data on 77,539 participants in the 100,000 Genomes Project. The study included 29,741 probands and 4,782 affected relatives assigned by expert clinicians to one or more of 220 specific disease classes encompassing a wide range of pathologies.

Clinical pathology selected abstracts

October 2024—Exposure to lead is associated with irreversible adverse effects on fetal and neonatal development. Because no reliable threshold exists for determining the impact of lead exposure on children, the CDC began using the term blood lead reference values to identify children with higher blood lead levels (BLLs). Limiting exposure to lead is critical to ensuring that vulnerable populations, such as fetuses, neonates, and children, are not at risk for adverse neurodevelopmental outcomes. Lead and inorganic lead compounds are classified as carcinogens, while such metals as mercury and cadmium are considered neurotoxicants. Studies have shown a significant correlation between post-transfusion BLLs in infants and lead levels in RBC units.

Anatomic pathology selected abstracts

October 2024—Screening for colorectal cancers can involve assessing mismatch repair deficiency or microsatellite instability to identify people with Lynch syndrome, the most common hereditary syndrome causing colorectal cancer. Advanced adenomas are considered immediate precursor lesions of colorectal cancer. The authors conducted a study in which they investigated the relevance of microsatellite instability screening of advanced adenomas for Lynch syndrome in population screening. They selected advanced adenomas (n=1,572) from the Dutch colorectal cancer population screening program. All were reviewed and met one or more of the following criteria: tubulovillous (n=848, 54 percent) or villous (n=118, 7.5 percent) adenoma, diameter of 1 cm or more (n=1,286, 82 percent), or high-grade dysplasia (n=176, 11 percent).

Molecular pathology selected abstracts

October 2024—Huntington disease is a neurodegenerative disease caused by abnormal CAG trinucleotide repeats in exon one of the HTT gene, in which the number of CAG repeats affects disease presentation. Alleles with 40 or more CAG (cytosine, adenine, guanine) repeats are fully penetrant and age at disease onset is inversely correlated with number of repeats, while 36 to 39 CAG repeats are associated with reduced penetrance and fewer than 36 are not considered to cause Huntington disease. It is thought that inherited CAG repeats may undergo somatic expansion until a harmful threshold is reached before the degenerative process begins.

Pathology informatics selected abstracts

October 2024—The authors conducted a study to evaluate the Genius digital diagnostic system compared with manual light microscopy diagnosis using ThinPrep Pap test slides. Six cytologists and three cytopathologists participated in the study. They received 1.5 days of training on the Genius digital system from the manufacturer (Hologic, Marlborough, Mass.). They then analyzed 319 ThinPrep Pap test cases in the authors’ institutional cytology archive that represented a range of Bethesda System categories typically encountered in routine practice. The study participants assessed diagnostic accuracy by comparing digital and manual results to the original Pap test diagnosis, which was considered the reference diagnosis, or ground truth.

MARKETPLACE

TRENDING